C. Diff Infection
‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.
Q&A: ‘Future is bright’ for use of microbiota therapeutics in patients with IBD
In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.
C. difficile bacterium strengthens by cooperating with Enterococcus, other gut microbes
The bacterium Clostridioides difficile tends to “cooperate” with microorganisms in the gastrointestinal tract, such as the pathogen Enterococcus, which can help the bacterium thrive, according to a study published in Nature.
Patients with CDI given ridinilazole had sustained clinical response, fewer recurrences
WASHINGTON — Nearly three out of every four patients with Clostridioides difficile infection being treated with ridinilazole had a sustained clinical response, according to data presented at IDWeek.